Literature DB >> 8703906

Identification of residues critical to the activity of human granulocyte colony-stimulating factor.

J F Reidhaar-Olson1, J A De Souza-Hart, H E Selick.   

Abstract

Alanine scanning mutagenesis of human granulocyte colony-stimulating factor (G-CSF) was used to identify residues critical for the cell-proliferative activity of the protein. Fifty-eight residues, most of them on the protein surface, were independently mutated to alanine. Most of the variants retained full biological activity; however, 15 mutants were significantly impaired in their ability to stimulate bone marrow cell proliferation in vitro. Four of these variants contain mutations at buried residues and two have substitutions at side chains involved in intramolecular hydrogen bonds. The remaining nine down mutations identify two regions on the surface of the molecule important for biological activity. Consistent with these observations, measurements of binding to NFS-60 cells indicate that the residues most important for receptor binding are Lys40 and Phe144 in site 1 and Glu19 in site 2. In addition to these residues, Val48 and Leu49 in site 1 and Leu15, Asp112, and Leu124 in site 2 are also important for biological activity. These results suggest the presence of two binding sites on the cytokine surface required for dimerization of the G-CSF receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8703906     DOI: 10.1021/bi952705x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Characterization of the receptor binding determinants of granulocyte colony stimulating factor.

Authors:  D C Young; H Zhan; Q L Cheng; J Hou; D J Matthews
Journal:  Protein Sci       Date:  1997-06       Impact factor: 6.725

Review 2.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

3.  Determination of Critical Quality Attributes for a Biotherapeutic in the QbD Paradigm: GCSF as a Case Study.

Authors:  Sumit K Singh; Deepak Kumar; Anurag S Rathore
Journal:  AAPS J       Date:  2017-09-05       Impact factor: 4.009

4.  Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening.

Authors:  Peizhi Luo; Robert J Hayes; Cheryl Chan; Diane M Stark; Marian Y Hwang; Jonathan M Jacinto; Padmaja Juvvadi; Helen S Chung; Anirban Kundu; Marie L Ary; Bassil I Dahiyat
Journal:  Protein Sci       Date:  2002-05       Impact factor: 6.725

5.  pH Dependence of structural stability of interleukin-2 and granulocyte colony-stimulating factor.

Authors:  Margaret Speed Ricci; Casim A Sarkar; Eric M Fallon; Douglas A Lauffenburger; David N Brems
Journal:  Protein Sci       Date:  2003-05       Impact factor: 6.725

6.  Homodimeric cross-over structure of the human granulocyte colony-stimulating factor (GCSF) receptor signaling complex.

Authors:  Taro Tamada; Eijiro Honjo; Yoshitake Maeda; Tomoyuki Okamoto; Matsujiro Ishibashi; Masao Tokunaga; Ryota Kuroki
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

7.  Characterization of stress-exposed granulocyte colony stimulating factor using ELISA and hydrogen/deuterium exchange mass spectrometry.

Authors:  Daisuke Tsuchida; Katsuyoshi Yamazaki; Satoko Akashi
Journal:  J Am Soc Mass Spectrom       Date:  2014-07-29       Impact factor: 3.109

8.  Effect of a structurally modified human granulocyte colony stimulating factor, G-CSFa, on leukopenia in mice and monkeys.

Authors:  Yongping Jiang; Wenhong Jiang; Yuchang Qiu; Wei Dai
Journal:  J Hematol Oncol       Date:  2011-06-13       Impact factor: 17.388

9.  Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity.

Authors:  Archita Agrawal; Sebastian Parlee; Diego Perez-Tilve; Pengyun Li; Jia Pan; Piotr A Mroz; Ann Maria Kruse Hansen; Birgitte Andersen; Brian Finan; Alexei Kharitonenkov; Richard D DiMarchi
Journal:  Mol Metab       Date:  2018-05-11       Impact factor: 7.422

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.